Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome.

par Trimoreau, F, François, B, Desachy, A, Besse, A, Vignon, P, Denizot, Y
Publié 2000

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

par Besse, L, Kraus, M, Besse, A, Bader, J, Silzle, T, Mehrling, T, Driessen, C
Publié dans Blood Cancer J (2017)

Personalized medicine approach confirms a milder case of ABAT deficiency

par Besse, A., Petersen, A. K., Hunter, J. V., Appadurai, V., Lalani, S. R., Bonnen, P. E.
Publié dans Mol Brain (2016)

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

par Besse, A, Stolze, S C, Rasche, L, Weinhold, N, Morgan, G J, Kraus, M, Bader, J, Overkleeft, H S, Besse, L, Driessen, C
Publié dans Leukemia (2018)

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

par Soriano, G P, Besse, L, Li, N, Kraus, M, Besse, A, Meeuwenoord, N, Bader, J, Everts, B, den Dulk, H, Overkleeft, H S, Florea, B I, Driessen, C
Publié dans Leukemia (2016)